Evidence map›Paper›PMID 32547236›Full record

ArticleCancer management and research2020

SOX10 - A Novel Marker for the Differential Diagnosis of Breast Metaplastic Squamous Cell Carcinoma.

Jialin Qi, Zhenmin Hu, Heng Xiao, Ruijie Liu, Wei Guo, Zhichun Yang, Kewen Ma, Shitong Su, Ping Tang, Xunjian Zhou and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer management and research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Jialin Qi *Department of Pathology, School of Basic Medical Science, Central South University, Changsha 410013, People's Republic of China.
Zhenmin Hu *Department of Pathology, School of Basic Medical Science, Central South University, Changsha 410013, People's Republic of China.
Heng XiaoDepartment of Pathology, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, People's Republic of China.
Ruijie LiuDepartment of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan 410078, People's Republic of China.
Wei GuoDepartment of Pathology, Hunan Provincial People's Hospital, Changsha, Hunan 410005, People's Republic of China.
Zhichun YangDepartment of Pharmacology, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha 410013, People's Republic of China.
Kewen MaDepartment of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan 410078, People's Republic of China.
Shitong SuDepartment of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan 410078, People's Republic of China.
Ping TangDepartment of Pathology, School of Basic Medical Science, Central South University, Changsha 410013, People's Republic of China.
Xunjian ZhouDepartment of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan 410078, People's Republic of China.
Jianhua ZhouDepartment of Pathology, School of Basic Medical Science, Central South University, Changsha 410013, People's Republic of China.
Kuansong WangDepartment of Pathology, School of Basic Medical Science, Central South University, Changsha 410013, People's Republic of China.
Central South University · CNXiangya Hospital Central South University · CNHunan Provincial People's Hospital · CNThird Xiangya Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionDifferential diagnosis of metaplastic squamous cell carcinoma of breast (MSCCB) is difficult. In particular, in terms of metastatic MSCCB, because of the low speciality of traditional markers such as mammaglobin, gross cystic disease fluid protein-15 (GCDFP-15) and GATA binding protein 3 (GATA3), the most common problem is differentiating the spread of MSCCB to the lung from a primary lung squamous cell carcinoma. It is urgently required to explore a novel marker to aid in differential diagnosis.

aimThe aim of this study is to explore a novel marker to aid in the differential diagnosis of MSCCB from other squamous cell carcinomas (SCC) in other organs.

methodsWe tested the expression of SOX10 in 375 human SCC specimens with immunohistochemistry (IHC).

resultsIn a series of 20 MSCCB, 9 (45%) were positive for SOX10. All of them were triple-negative MSCCB. Conversely, SOX10 was totally negative in another 205 SCC originating from lung, skin, cervix, oral mucosa, and esophagus. In a series of 150 triple-negative breast cancer and their metastatic foci, SOX10 labeling in the primary tumor and metastasis was 78% and 79.3%, respectively, and the agreement rate was 97.3% (

conclusionOur findings demonstrate that SOX10 was recommended for differentiating MSCCB from non-mammary metastasis to the breast, as well as for distinguishing primary SCC from metastatic MSCCB, and SOX10 may be valuable in the pathological diagnosis of breast-derived metaplastic squamous cell carcinoma.

Indexed as

breastdifferential diagnosislungSOX10squamous cell carcinoma

Identifiers

PMID32547236
PMCPMC7266319
OpenAlexW3032287451

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.